RxDoctor Payments Data

Megan Schollenberger

Primary Care · Gaithersburg, MDNPI 1952643116

Payments from drug & device makers

What this record shows

E.r. Squibb & Sons, L.L.C. accounts for 61.6% of it on its own, with 12 other manufacturers making up the rest.

$1,294in general payments, 2019–2025

Across 16 payments — averaging $80.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • E.r. Squibb & Sons, L.L.C.$797
  • Regeneron$116
  • Array Biopharma Inc$92
  • AstraZeneca$73
  • Stemline Therapeutics Inc.$34
  • Johnson & Johnson$34
  • plus $148 from 7 others

What the payments were for

  • Consulting fees$67552%
  • Food & beverage$61948%

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,294 in reported general payments places this provider in the 75th percentile of 191 primary care providers in Maryland.

See all primary care providers in Maryland

Medicare billing

Part B allowed, 2024
$63,518
Medicare patients
170
Services billed
616

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BraftoviEncorafenib21$341,268
MektoviBinimetinib21$258,838
EliquisApixaban27$19,388
XareltoRivaroxaban29$14,360
Hydrocortisone39$1,330
Levothyroxine Sodium98$575
Triamcinolone Acetonide25$418
Pantoprazole Sodium33$274
Tramadol Hcl15$250
Prednisone45$191
Gabapentin22$121
Oxycodone Hcl15$100
Amlodipine Besylate13$21

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Array Biopharma IncBraftovi, Mektovi$92$600,10542 claims
Johnson & JohnsonXarelto$34$14,36029 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 191 primary care providers in Maryland.

Other primary care in Gaithersburg

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →